115 related articles for article (PubMed ID: 15690072)
1. Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy.
Kajiguchi T; Yamamoto K; Sawa M; Emi N; Naoe T
Leukemia; 2005 Apr; 19(4):674-6. PubMed ID: 15690072
[No Abstract] [Full Text] [Related]
2. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
3. Arsenic trioxide.
Wilkinson K
Clin J Oncol Nurs; 2001; 5(5):237-8. PubMed ID: 11899773
[No Abstract] [Full Text] [Related]
4. Oral arsenic treatment of leukemia and the risk of porphyria.
Au WY; Tam S; Fong BM; Kwong YL
Leuk Res; 2009 Apr; 33(4):598-600. PubMed ID: 18829106
[No Abstract] [Full Text] [Related]
5. Clinical effects of arsenic trioxide by slowing-intravenous infusion on acute promyelocyte leukemia.
Zhou J; Meng R; Yang BF
Chin Med Sci J; 2005 Jun; 20(2):137. PubMed ID: 16075757
[No Abstract] [Full Text] [Related]
6. Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected].
Au WY; Tam S; Fong BM; Ho KL; Tam PC; Kwong YL
Leuk Lymphoma; 2007 Nov; 48(11):2233-4. PubMed ID: 17926176
[No Abstract] [Full Text] [Related]
7. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure.
Hai JJ; Gill H; Tse HF; Kumana CR; Kwong YL; Siu CW
Ann Hematol; 2015 Mar; 94(3):501-3. PubMed ID: 25079038
[No Abstract] [Full Text] [Related]
8. Use of Novoseven for arsenic trioxide-induced bleeding in PML.
Alimoghaddam K; Ghavamzadeh A; Jahani M
Am J Hematol; 2006 Sep; 81(9):720. PubMed ID: 16804937
[No Abstract] [Full Text] [Related]
9. High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia.
Yamakura M; Tsuda K; Ugai T; Sugihara H; Nisihida Y; Takeuchi M; Matsue K
Acta Haematol; 2014; 131(2):76-7. PubMed ID: 24081111
[No Abstract] [Full Text] [Related]
10. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
[TBL] [Abstract][Full Text] [Related]
11. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient.
Huang CH; Chen WJ; Wu CC; Chen YC; Lee YT
Pacing Clin Electrophysiol; 1999 Jun; 22(6 Pt 1):965-7. PubMed ID: 10392399
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide.
Au WY; Cheung GT; Yuen TW; Kumana CR; Kwong YL
Arch Intern Med; 2005 May; 165(9):1067-8. PubMed ID: 15883249
[No Abstract] [Full Text] [Related]
13. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
Au WY; Tam S; Kwong YL
Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
[No Abstract] [Full Text] [Related]
14. Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction.
Roberts TF; Sprague K; Schenkein D; Miller KB; Relias V
Blood; 2000 Dec; 96(12):4000-1. PubMed ID: 11186272
[No Abstract] [Full Text] [Related]
15. [Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
Ercilla Liceaga M; Andueza Granados K; Fernández González I; Barcia Romero MJ
Farm Hosp; 2003; 27(2):93-100. PubMed ID: 12717564
[TBL] [Abstract][Full Text] [Related]
16. Hyperleukocytosis from arsenic trioxide.
Levy M; Wofford MM; Powell BL; McLean TW
Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
[TBL] [Abstract][Full Text] [Related]
17. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
[No Abstract] [Full Text] [Related]
18. Ancient remedy performs new tricks.
Mervis J
Science; 1996 Aug; 273(5275):578. PubMed ID: 8701308
[No Abstract] [Full Text] [Related]
19. Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.
Takeshita A; Uehara A; Shinjo K; Naito K; Sahara N; Yamazaki K; Katoh H; Kamikawa T; Ohnishi K; Maekawa M; Hayashi H; Ohno R
Leukemia; 2004 Mar; 18(3):647-8. PubMed ID: 14671633
[No Abstract] [Full Text] [Related]
20. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin F; Roncolato F; Ho WK
Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]